Skip to main content

Friday, Jan. 8, 2016, 42 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $975.00 to $3,560,848.74.

Highlighted Stocks Traded by Insiders:

Mentor Graphics (MENT) - FREE Research Report

Mcmanus Patrick, who is Director at Mentor Graphics, bought 2,000 shares at $17.13 on Jan. 8, 2016. Following this transaction, the Director owned 52,853 shares meaning that the stake was boosted by 3.93% with the 2,000-share transaction.

The shares most recently traded at $17.28, up $0.15, or 0.87% since the insider transaction. Historical insider transactions for Mentor Graphics go as follows:

  • 4-Week # shares bought: 4,000
  • 4-Week # shares sold: 170,000
  • 12-Week # shares bought: 14,000
  • 12-Week # shares sold: 170,000
  • 24-Week # shares bought: 14,000
  • 24-Week # shares sold: 170,000

The average volume for Mentor Graphics has been 1.6 million shares per day over the past 30 days. Mentor Graphics has a market cap of $2.0 billion and is part of the technology sector and computer software & services industry. Shares are down 6.73% year-to-date as of the close of trading on Friday.

Mentor Graphics Corporation provides electronic design automation software and hardware solutions to automate the design, analysis, and testing of electro-mechanical systems, electronic hardware, and embedded systems software. The stock currently has a dividend yield of 1.26%. The company has a P/E ratio of 13.7. Currently, there are no analysts who rate Mentor Graphics a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MENT - FREE

TheStreet Quant Ratings

rates Mentor Graphics as a

TheStreet Recommends

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full

Mentor Graphics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Harris & Harris Group (TINY) - FREE Research Report

Jamison Douglas W, who is Chairman, CEO at Harris & Harris Group, bought 1,010 shares at $2.17 on Jan. 8, 2016. Following this transaction, the Chairman, CEO owned 203,789 shares meaning that the stake was boosted by 0.5% with the 1,010-share transaction.

Ushio Misti, who is Executive Vice President at Harris & Harris Group, bought 755 shares at $2.17 on Jan. 8, 2016. Following this transaction, the Executive Vice President owned 111,495 shares meaning that the stake was boosted by 0.68% with the 755-share transaction.

The shares most recently traded at $2.15, down $0.02, or 0.93% since the insider transaction. Historical insider transactions for Harris & Harris Group go as follows:

  • 4-Week # shares bought: 2,500
  • 12-Week # shares bought: 18,498
  • 24-Week # shares bought: 39,497

The average volume for Harris & Harris Group has been 67,900 shares per day over the past 30 days. Harris & Harris Group has a market cap of $66.8 million and is part of the financial sector and financial services industry. Shares are down 2.73% year-to-date as of the close of trading on Friday.

Harris & Harris Group, Inc. is a venture capital firm specializing in early stage investments. It is a BDC. Currently, there are no analysts who rate Harris & Harris Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TINY - FREE

TheStreet Quant Ratings

rates Harris & Harris Group as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full

Harris & Harris Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

OncoMed Pharmaceuticals (OMED) - FREE Research Report

Patel Sunil, who is Officer at OncoMed Pharmaceuticals, sold 2,162 shares at $22.28 on Jan. 8, 2016. Following this transaction, the Officer owned 17,838 shares meaning that the stake was reduced by 10.81% with the 2,162-share transaction.

Hoey Timothy, who is SVP, Cancer Biology at OncoMed Pharmaceuticals, sold 2,162 shares at $22.28 on Jan. 8, 2016. Following this transaction, the SVP, Cancer Biology owned 47,181 shares meaning that the stake was reduced by 4.38% with the 2,162-share transaction.

Dupont Jakob, who is SVP & Chief Medical Officer at OncoMed Pharmaceuticals, sold 2,162 shares at $22.28 on Jan. 8, 2016. Following this transaction, the SVP & Chief Medical Officer owned 20,642 shares meaning that the stake was reduced by 9.48% with the 2,162-share transaction.

Gurney Austin, who is Officer at OncoMed Pharmaceuticals, sold 2,162 shares at $22.28 on Jan. 8, 2016. Following this transaction, the Officer owned 33,257 shares meaning that the stake was reduced by 6.1% with the 2,162-share transaction.

Hager Alicia J., who is VP & General Counsel at OncoMed Pharmaceuticals, sold 1,623 shares at $22.28 on Jan. 8, 2016. Following this transaction, the VP & General Counsel owned 13,377 shares meaning that the stake was reduced by 10.82% with the 1,623-share transaction.

The shares most recently traded at $18.83, down $3.45, or 18.3% since the insider transaction. Historical insider transactions for OncoMed Pharmaceuticals go as follows:

  • 4-Week # shares bought: 11,210
  • 4-Week # shares sold: 14,000
  • 12-Week # shares bought: 11,210
  • 12-Week # shares sold: 14,000
  • 24-Week # shares bought: 24,350
  • 24-Week # shares sold: 28,000

The average volume for OncoMed Pharmaceuticals has been 139,400 shares per day over the past 30 days. OncoMed Pharmaceuticals has a market cap of $658.5 million and is part of the health care sector and drugs industry. Shares are down 8.65% year-to-date as of the close of trading on Friday.

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Currently, there are 4 analysts who rate OncoMed Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMED - FREE

TheStreet Quant Ratings

rates OncoMed Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

OncoMed Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.